Edwards Lifesciences outlines 8%–10% sales growth and $2.90–$3.05 EPS guidance for 2026 while advancing SAPIEN and TMTT platforms (NYSE:EW)

Edwards(US:EW) Seeking Alpha·2026-02-11 00:55

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Edwards Lifesciences outlines 8%–10% sales growth and $2.90–$3.05 EPS guidance for 2026 while advancing SAPIEN and TMTT platforms (NYSE:EW) - Reportify